Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in: BMC Public Health 1/2016

Open Access 01-12-2016 | Research article

Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia

Authors: Aurélien Jamotte, Chui Fung Chong, Andrew Manton, Bérengère Macabeo, Mondher Toumi

Published in: BMC Public Health | Issue 1/2016

Login to get access

Abstract

Background

Annual trivalent influenza vaccines (TIV) containing three influenza strains (A/H1N1, A/H3N2, and one B) have been recommended for the prevention of influenza. However, worldwide co-circulation of two distinct B lineages (Victoria and Yamagata) and difficulties in predicting which lineage will predominate each season have led to the development of quadrivalent influenza vaccines (QIV), which include both B lineages. Our analysis evaluates the public health benefit and associated influenza-related costs avoided which would have been obtained by using QIV rather than TIV in Australia over the period 2002–2012.

Methods

A static model stratified by age group was used, focusing on people at increased risk of influenza as defined by the Australian vaccination recommendations. B-lineage cross-protection was accounted for. We calculated the potential impact of QIV compared with TIV over the seasons 2002–2012 (2009 pandemic year excluded) using Australian data on influenza circulation, vaccine coverage, hospitalisation and mortality rates as well as unit costs, and international data on vaccine effectiveness, influenza attack rate, GP consultation rate and working days lost. Third-party payer and societal influenza-related costs were estimated in 2014 Australian dollars. Sensitivity analyses were conducted.

Results

Using QIV instead of TIV over the period 2002–2012 would have prevented an estimated 68,271 additional influenza cases, 47,537 GP consultations, 3,522 hospitalisations and 683 deaths in the population at risk of influenza. These results translate into influenza-related societal costs avoided of $46.5 million. The estimated impact of QIV was higher for young children and the elderly. The overall impact of QIV depended mainly on vaccine effectiveness and the influenza attack rate attributable to the mismatched B lineage.

Conclusion

The broader protection offered by QIV would have reduced the number of influenza infections and its related complications, leading to substantial influenza-related costs avoided.
Appendix
Available only for authorised users
Literature
1.
2.
Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB. Prevention and control of influenza: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2004;53:1–40.PubMed
3.
Newall AT, Scuffham PA. Influenza-related disease: the cost to the Australian healthcare system. Vaccine. 2008;26:6818–23.CrossRefPubMed
4.
5.
6.
Australian Technical Advisory Group on Immunisation (ATAGI). The Australian immunisation handbook 10th ed (2015 update). Canberra: Australian Government Department of Health; 2015.
7.
8.
World Health Organization (WHO). Vaccines against influenza WHO position paper – November 2012. Wkly Epidemiol Rec. 2012;87:461–76.
9.
Commission of the European Communities. Council recommendation on seasonal influenza vaccination. 2009.
10.
11.
12.
Barr IG, Jelley LL. The coming era of quadrivalent human influenza vaccines: who will benefit? Drugs. 2012;72:2177–85.CrossRefPubMed
13.
14.
Tricco AC, Chit A, Soobiah C, Hallett D, Meier G, Chen MH, et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med. 2013;11:153.CrossRefPubMedPubMedCentral
15.
DiazGranados CA, Denis M, Plotkin S. Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials. Vaccine. 2012;31:49–57.CrossRefPubMed
16.
Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine. 2012;30:1993–8.CrossRefPubMed
17.
18.
19.
20.
Russel ME, Snell R, Thompson D, May E, Stewart S. Uncovering the burden of angina pectoris in Australia. Heart Lung Circ. 2004;13:S62–S3.
21.
Katzenellenbogen JM, Sanfilippo FM, Hobbs MS, Briffa TG, Ridout SC, Knuiman MW, et al. Variable effects of prevalence correction of population denominators on differentials in myocardial infarction incidence: a record linkage study in aboriginal and non-aboriginal Western Australians. J Clin Epidemiol. 2011;64:658–66.CrossRefPubMed
22.
23.
Jefferson T, Rivetti A, Di PC, Demicheli V, Ferroni E. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev. 2012;8:CD004879.
24.
Jefferson T, Di PC, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2010;7:CD001269.
25.
Jefferson T, Di PC, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev. 2010;2:CD004876.
26.
27.
28.
29.
30.
Newcombe J, Kaur R, Wood N, Seale H, Palasanthiran P, Snelling T. Prevalence and determinants of influenza vaccine coverage at tertiary pediatric hospitals. Vaccine. 2014;32:6364–8.CrossRefPubMed
31.
Clements KM, Meier G, McGarry LJ, Pruttivarasin N, Misurski DA. Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States. Hum Vaccin Immunother. 2014;10:1171–80.CrossRefPubMedPubMedCentral
32.
Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25:5086–96.CrossRefPubMed
33.
Newall AT, Wood JG, Macintyre CR. Influenza-related hospitalisation and death in Australians aged 50 years and older. Vaccine. 2008;26:2135–41.CrossRefPubMed
34.
35.
36.
37.
38.
Carrat F, Sahler C, Rogez S, Leruez-Ville M, Freymuth F, Le GC, et al. Influenza burden of illness: estimates from a national prospective survey of household contacts in France. Arch Intern Med. 2002;162:1842–8.CrossRefPubMed
39.
Esposito S, Cantarutti L, Molteni CG, Daleno C, Scala A, Tagliabue C, et al. Clinical manifestations and socio-economic impact of influenza among healthy children in the community. J Infect. 2011;62:379–87.CrossRefPubMed
40.
41.
42.
Prosser LA, Lavelle TA, Fiore AE, Bridges CB, Reed C, Jain S, et al. Cost-effectiveness of 2009 pandemic influenza A(H1N1) vaccination in the United States. PLoS One. 2011;6:e22308.CrossRefPubMedPubMedCentral
43.
O’Brien MA, Uyeki TM, Shay DK, Thompson WW, Kleinman K, McAdam A, et al. Incidence of outpatient visits and hospitalizations related to influenza in infants and young children. Pediatrics. 2004;113:585–93.CrossRefPubMed
44.
Mullooly JP, Bridges CB, Thompson WW, Chen J, Weintraub E, Jackson LA, et al. Influenza- and RSV-associated hospitalizations among adults. Vaccine. 2007;25:846–55.CrossRefPubMed
45.
Vijaykrishna D, Holmes EC, Joseph U, Fourment M, Su YC, Halpin R, et al. The contrasting phylodynamics of human influenza B viruses. Elife. 2015;4:e05055.CrossRefPubMedPubMedCentral
46.
Milne GJ, Halder N, Kelso JK, Barr IG, Moyes J, Kahn K, et al. Trivalent and quadrivalent influenza vaccination effectiveness in Australia and South Africa: results from a modelling study. Influenza Other Respir Viruses. 2016;10(4):324–32.CrossRefPubMedPubMedCentral
47.
Van Bellinghen LA, Meier G, Van VI. The potential cost-effectiveness of quadrivalent versus trivalent influenza vaccine in elderly people and clinical risk groups in the UK: a lifetime multi-cohort model. PLoS One. 2014;9:e98437.CrossRefPubMedPubMedCentral
48.
49.
Preaud E, Durand L, Macabeo B, Farkas N, Sloesen B, Palache A, et al. Annual public health and economic benefits of seasonal influenza vaccination: a European estimate. BMC Public Health. 2014;14:813.CrossRefPubMedPubMedCentral
50.
Keech M, Beardsworth P. The impact of influenza on working days lost: a review of the literature. Pharmacoeconomics. 2008;26:911–24.CrossRefPubMed
51.
Belshe RB. The need for quadrivalent vaccine against seasonal influenza. Vaccine. 2010;28 Suppl 4:D45–53.CrossRefPubMed
52.
53.
Irving SA, Patel DC, Kieke BA, Donahue JG, Vandermause MF, Shay DK, et al. Comparison of clinical features and outcomes of medically attended influenza A and influenza B in a defined population over four seasons: 2004–2005 through 2007–2008. Influenza Other Respir Viruses. 2012;6:37–43.CrossRefPubMed
54.
55.
Australian Department of Health. National notifiable diseases surveillance annual reports 2002–2012. 2015.
Metadata
Title
Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia
Authors
Aurélien Jamotte
Chui Fung Chong
Andrew Manton
Bérengère Macabeo
Mondher Toumi
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2016
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-016-3297-1

Other articles of this Issue 1/2016

BMC Public Health 1/2016 Go to the issue

Study protocol

A restaurant-based intervention to promote sales of healthy children’s menu items: the Kids’ Choice Restaurant Program cluster randomized trial

Research article

Factors associated with pre-ART loss-to-follow up in adults in rural KwaZulu-Natal, South Africa: a prospective cohort study

Research article

Treatment outcomes of childhood tuberculosis in Addis Ababa: a five-year retrospective analysis

Research article

How are self-rated health and diagnosed disease related to early or deferred retirement? A cross-sectional study of employees aged 55-64

Research article

Parental supply of alcohol to Australian minors: an analysis of six nationally representative surveys spanning 15 years

Research article

Secular trends and correlates of physical activity: The Tromsø Study 1979-2008